Online inquiry

IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13514MR)

This product GTTS-WQ13514MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets SNCA gene. The antibody can be applied in Parkinson's disease (PD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000345.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6622
UniProt ID P37840
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13514MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ849MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-155
GTTS-WQ8661MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ15264MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ7405MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ510MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ13936MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ740MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ10809MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA M777-16-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW